View ValuationPelthos Therapeutics 将来の成長Future 基準チェック /56Pelthos Therapeuticsは、65.9%と33.6%でそれぞれ年率65.9%で利益と収益が成長すると予測される一方、EPSはgrowで68.8%年率。主要情報65.9%収益成長率68.77%EPS成長率Biotechs 収益成長25.1%収益成長率33.6%将来の株主資本利益率n/aアナリストカバレッジGood最終更新日15 Jun 2026今後の成長に関する最新情報Breakeven Date Change • May 15The 7 analysts covering Pelthos Therapeutics previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 78% per year to 2027. The company is expected to make a profit of US$32.9m in 2028. Average annual earnings growth of 71% is required to achieve expected profit on schedule.Major Estimate Revision • Mar 26Consensus EPS estimates fall by 99%The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$5.96 to -US$11.85 per share. Revenue forecast unchanged at US$61.6m. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$58.33. Share price was steady at US$22.74 over the past week.Breakeven Date Change • Mar 08Forecast breakeven date pushed back to 2028The 6 analysts covering Pelthos Therapeutics previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of US$26.6m in 2028. Average annual earnings growth of 53% is required to achieve expected profit on schedule.Major Estimate Revision • Mar 03Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$18.0m to US$16.9m. Losses expected to increase from US$13.14 per share to US$14.51. Biotechs industry in the US expected to see average net income decline 8.5% next year. Consensus price target down from US$60.40 to US$58.00. Share price rose 4.0% to US$24.16 over the past week.すべての更新を表示Recent updatesNew Risk • May 17New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$35m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (409% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$35m). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$89.7m market cap).Breakeven Date Change • May 15The 7 analysts covering Pelthos Therapeutics previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 78% per year to 2027. The company is expected to make a profit of US$32.9m in 2028. Average annual earnings growth of 71% is required to achieve expected profit on schedule.お知らせ • May 01Pelthos Therapeutics Inc. to Report Q1, 2026 Results on May 14, 2026Pelthos Therapeutics Inc. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on May 14, 2026お知らせ • Apr 12Pelthos Therapeutics Inc. Announces Chief Financial Officer TransitionPelthos Therapeutics Inc. announced John M. Gay has been appointed Chief Financial Officer effective April 10, 2026. Mr. Gay succeeds Francis Knuettel II, who served as Pelthos’ Chief Financial Officer since July 2025. Mr. Gay has served as Senior Vice President, Finance & Accounting at Pelthos since 2025. He has more than 25 years of public company finance and accounting experience. Prior to joining Pelthos, he served as Chief Financial Officer of LNHC Inc. (then, a wholly owned subsidiary of Ligand Pharmaceuticals Inc.) and in senior finance roles at several publicly traded companies, including Furiex Pharmaceuticals, which was ultimately acquired by Forest Laboratories. He previously held roles at Deloitte and Arthur Andersen.お知らせ • Mar 31Pelthos Therapeutics Inc. Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye PainPelthos Therapeutics Inc. announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating CT2000 as a potential treatment for eye pain. Channel Pharmaceutical Corporation owns the rights to CT2000 and its NaV1.7 inhibitor pipeline and is conducting the clinical work through its Australian subsidiary. The placebo-controlled Phase 1b/2a clinical trial will evaluate the safety and clinical efficacy of CT2000 eye drop formulation in patients with moderate to severe dry eye disease with chronic eye pain. The trial will be an adaptive design with a Phase 1 ascending dose study (with acute ocular pain measures) and a Phase 2a maximum tolerated dose study with a 28-day dosing period. Results are anticipated at the end of 2026. In May 2025, Channel announced that it achieved its predefined endpoints in two pre-clinical animal models of its CT2000 eye drop formulations for the treatment of acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease. CT2000 is a novel ophthalmic formulation of Channel’s CC8464 that targets the sodium ion-channel known as NaV1.7, a key factor in the propagation of pain signals in peripheral nerves. NaV1.7 channels are widely expressed in the corneal nerve plexus, making it an attractive target for treating eye pain. Eye pain may occur with various conditions, including severe dry eye disease, trauma and surgery. Existing therapies for eye pain, including steroids, topical non-steroidal anti-inflammatory agents, lubricants, and local anesthetics, are limited in their effectiveness and/or limited in the duration that they may be prescribed because of safety issues. It is estimated that the global chronic ocular pain market will reach $5.3 billion by 2032.Major Estimate Revision • Mar 26Consensus EPS estimates fall by 99%The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$5.96 to -US$11.85 per share. Revenue forecast unchanged at US$61.6m. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$58.33. Share price was steady at US$22.74 over the past week.お知らせ • Mar 09Pelthos Therapeutics Inc. to Report Q4, 2025 Results on Mar 19, 2026Pelthos Therapeutics Inc. announced that they will report Q4, 2025 results on Mar 19, 2026Breakeven Date Change • Mar 08Forecast breakeven date pushed back to 2028The 6 analysts covering Pelthos Therapeutics previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of US$26.6m in 2028. Average annual earnings growth of 53% is required to achieve expected profit on schedule.Major Estimate Revision • Mar 03Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$18.0m to US$16.9m. Losses expected to increase from US$13.14 per share to US$14.51. Biotechs industry in the US expected to see average net income decline 8.5% next year. Consensus price target down from US$60.40 to US$58.00. Share price rose 4.0% to US$24.16 over the past week.お知らせ • Jan 13Pelthos Therapeutics Inc. announced that it expects to receive $50 million in fundingPelthos Therapeutics Inc. announced that it has entered into a Venture Loan and Security Agreement with new lender Horizon Technology Finance Corporation, a fund managed by, Horizon Technology Finance Management, LLC for an aggregate principal amount of up to $50 million on January 12, 2026. The company has borrowed $30 million of Term Loans on the same date. The remaining $20 million of Terms Loans may be borrowed under the Loan Agreement upon the achievement by the Company of certain milestones set forth in the Loan Agreement. The Loan Agreement accrue interest at a rate equal to the prime rate plus 3.75% with the prime rate having a floor of 6.75%. The Term Loans are repayable in monthly interest-only payments from March 1, 2026 until February 1, 2029. After the expiration of the Interest-Only Payment Period, beginning on March 1, 2029, the Term Loans will be repayable in 24 equal monthly payments of principal and accrued interest until maturity. if the Borrowers achieve a trailing twelve-month consolidated net revenue of at least $75.0 million, the Term Loans will be repayable in monthly interest-only payments from March 1, 2026 until February 1, 2030. After the expiration of the Extended Interest-Only Payment Period, the Term Loans will be repayable in 12 equal monthly payments of principal and accrued interest until maturity. The Term Loans will mature on January 31, 2031. The company paid a commitment fee in the amount of $300,000 on the Closing Date. The company will pay an additional commitment fee in the amount of 1.0% of the principal amount of the last six Term Loans concurrently with the funding of those six Term Loans.Recent Insider Transactions • Nov 28Independent Director recently sold US$280k worth of stockOn the 25th of November, Ezra Friedberg sold around 10k shares on-market at roughly US$28.03 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.お知らせ • Nov 17Pelthos Therapeutics Inc., Annual General Meeting, Dec 17, 2025Pelthos Therapeutics Inc., Annual General Meeting, Dec 17, 2025.お知らせ • Nov 08Pelthos Therapeutics Inc. announced that it has received $18 million in funding from Ligand Pharmaceuticals IncorporatedPelthos Therapeutics Inc. has entered into entered into a securities purchase agreement with certain investors, including Ligand Pharmaceuticals and issued $18,000,000 senior secured notes which are convertible into shares of the Company’s common stock, par value $0.0001 per share on November 6, 2025. The notes have interest at a rate of 8.5% per annum, payable quarterly in arrears. The Notes will mature on November 6, 2027, unless earlier repurchased, redeemed or converted into shares of common stock in accordance with their terms. The Notes will be convertible at an initial conversion price of $34.442.お知らせ • Nov 05Pelthos Therapeutics Inc. to Report Q3, 2025 Results on Nov 13, 2025Pelthos Therapeutics Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 13, 2025お知らせ • Oct 10Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum ContagiosumPelthos Therapeutics Inc. announced the launch of Moms against Molluscum, a movement to unite mothers, parents, and other caregivers navigating molluscum contagiosum. The Moms Against Molluscum movement encourages people managing this highly contagious skin infection to visit Moms AgainstMolluscum.com to share their stories and access information about new treatment options, including ZELSUVMI™? (berdazimer) topical gel, 10.3%. Molluscum is a poxvirus and one of the most common skin infections seen by dermatologists, pediatric dermatologists, and pediatricians. The once-daily prescription medication is effective, well-tolerated, and convenient for at-home or on-the-go application and can be used to treat molluscum infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infection.New Risk • Aug 28New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 428% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-US$6.5m). Earnings have declined by 52% per year over the past 5 years. Shareholders have been substantially diluted in the past year (428% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$72.2m market cap).お知らせ • Jul 10Pelthos Therapeutics Launches Zelsuvmi™? (Berdazimer) Topical Gel 10.3%, the First and Only Fda-Approved At-Home Treatment for Molluscum ContagiosumPelthos Therapeutics Inc. announced the launch of ZELSUVMI™? (berdazimer) topical gel, 10.3%, for the treatment of molluscumcontagiosum (molluscum) in adults and pediatric patients one year of age and older. ZELSUVMI received a novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infections, a highly contagious viral skin condition. The once-daily prescription medication is effective, well tolerated, and convenient for at-home or on-the-go application and can be used to treat infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI was studied in the largest randomized clinical trial for the treatment of mollusum. The trial was a multicenter, randomized, double-blind, vehicle controlled, parallel-group, Phase 3 study of the efficacy and safety of ZELSUVMI in 891 patients. These patients have waiting a long time for an at-home treatment option. ZELSUVMI is now commercially available through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies via prescription.お知らせ • Jul 03+ 3 more updatesPelthos Therapeutics Inc. Announces Management ChangesOn July 1, 2025 (the “Closing Date”), Pelthos Therapeutics Inc., a Nevada corporation (formerly known as “Channel Therapeutics Corporation” (the “Company”)), consummated the previously announced merger transaction contemplated by that certain Agreement and Plan of Merger, dated as of April 16, 2025 (the “Merger Agreement”), by and among the Company, CHRO Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), LNHC Inc., a Delaware corporation (“LNHC”), and solely for the purposes of Article III thereof, a Ligand Pharmaceuticals Incorporated, a Delaware corporation and the parent of LNHC (“Ligand”). Pursuant to the Merger Agreement, (i) Merger Sub merged with and into LNHC, with LNHC as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of the Company (the “Merger”) and (ii) the Company’s name was changed from Channel Therapeutics Corporation to Pelthos Therapeutics Inc. In connection with the Merger and pursuant to the terms of the Merger Agreement, at the Effective Time, Francis Knuettel II, Todd Davis, Ezra Friedberg and Chia-Lin Simmons each resigned from the Company’s board of directors (the “Board”). In addition, the size of the Board was increased from five to seven directors. At the Effective Time, one director selected by the Company, namely Dr. Richard Malamut, one director who is the newly-elected Chief Executive Officer of the Company, namely Scott Plesha, four directors selected by LNHC, namely Peter Greenleaf, Matthew Pauls, Todd Davis and Richard Baxter, and one member selected by Nomis Bay, namely Ezra Friedberg, were each appointed to serve as a director of the Company until the next annual meeting of stockholders to be held after the Closing Date or until a successor is duly elected and qualified, or until each such director’s earlier resignation or removal. Effective as of the Closing Date, the following committees of the Board were constituted as follows: Audit Committee: Ezra Friedberg (Chair) and Matthew Pauls. Compensation Committee: Dr. Richard Malamut and Matthew Pauls (Chair). Nominating and Corporate Governance Committee: Dr. Richard Malamut and Peter Greenleaf (Chair). In connection with the Merger, on the Closing Date, Francis Knuettel’s employment as Chief Executive Officer, and President, Treasurer and Secretary of the Company terminated. Additionally, on the Closing Date, Dr. Eric Lang’s employment as Chief Medical Officer of the Company was terminated. In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, the following individuals were appointed to serve as executive officers of the Company: Scott Plesha, age 61, as President and Director. Sai Rangarao, age 41, as Chief Commercial Officer. Sai Rangarao serves as Senior Vice President, Head of Sales, Marketing & Commercial Operations at Pelthos. Mr. Rangarao joined Pelthos in March 2024. He has more than a decade of experience leading, launching, and marketing large and highly differentiated pharmaceutical products, including Otezla®, the only approved oral systemic therapy with a broad indication. Prior to joining Pelthos, Mr. Rangarao was Vice President of Marketing at Collegium Pharmaceutical, where he led marketing for the full product portfolio and Neurology sales. He joined Collegium from BioDelivery Sciences International (BDSI), which was acquired by Collegium in 2022. Under Mr. Rangarao’s leadership as Vice President of Marketing and Commercial Operations at BDSI, the company expanded its pain and neurology product portfolio and increased market share of the company’s lead product BELBUCA®, ultimately leading to the successful sale to Collegium. Before BDSI, he was Head of Dermatology Marketing at Celgene Corporation. At Celgene, Mr. Rangarao was responsible for the commercial efforts of Otezla in dermatology for three consecutive years leading to significant year-over-year market share growth until the product was sold to Amgen for $13 billion. He began his career at Novartis Pharmaceuticals, where he held roles of increasing responsibility across Global R&D, Sales Force Effectiveness, Multichannel, and In-Line Marketing. Mr. Rangarao also served as a key member of the commercial and marketing organization at Novartis that launched COSENTYX® in the U.S. Mr. Rangarao earned an MS in Bioscience Regulatory Affairs from The Johns Hopkins University, an MBA and MS from the New Jersey Institute of Technology, and a BS in Computer Science from Indiana University of Pennsylvania.New Risk • May 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$4.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.4m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-US$4.2m). Earnings have declined by 57% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$6.47m market cap).お知らせ • May 15Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using Its Nav1.7 Inhibitor in Multiple Preclinical in Vivo ModelsChannel Therapeutics Corporation announced that it has achieved its predefined endpoints in two pre-clinical animal models of the Company's eye drop formulations ("CT2000") for the treatment of both acute ocular pain as well as chronic ocular surface pain commonly associated with dry eye disease. In the first trial, rabbits were treated with capsaicin (i.e., Pepper spray) to mimic an acute ocular insult in a common, validated model for acute eye pain studies. Following the capsaicin treatment, the rabbits were treated with CT2000, which was dosed four times over a 24-hour period. Pain was measured by the number of paw wipes over 60 seconds (paw wipes are a recognized surrogate of eye pain in animal models). The results showed that CT2000 significantly reduced the number of paw wipes within 15 minutes of administration of capsaicin and that CT2000 continued to show efficacy over a 60-minute period following administration. This eye pain model was only validated for a short duration, with the results summarized in the following graph: Trial Two: In the second trial, benzalkonium chloride was instilled in mice eyes over a multiday period to create a model of dry eye disease (the study was repeated twice). BAC is a detergent that irritates the eyes and simulates dry eye disease. It is this existing market that the Company intends to target with CT2000, in addition to the post operative pain market with recently announced data on the efficacy of Depot formulation, which will be developed for use in post operative nerve blocks.お知らせ • Dec 19Channel Therapeutics Announces Positive Efficacy Data for A Depot Formulation of A NaV1.7 Inhibitor in A Preclinical in Vivo Nerve Block ModelChannel Therapeutics Corporation, announced that it achieved its endpoints in two pre-clinical in vivo models of the Company’s nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration. About the trial The Company performed a thermal hyperalgesia test in rodents with a placebo arm, bupivacaine arm and four arms of the main formulations of the Company’s molecule. The Company also performed a mechanical allodynia test in rodents with the same arms as above. For both models, the drugs were administered as a sciatic nerve block. All four Company formulations showed a depot effect in excess of four days, an improvement over bupivacaine, the current standard of care. Results The results of the thermal hyperalgesia results are shown in the chart below. After thirty minutes, three of the four formulations showed materially better efficacy than bupivacaine, with each of the three being statistically superior to placebo for more than two days longer than bupivacaine. One of the formulations remained statistically superior to placebo for more than four days. Further, as NaV1.7 does not have an impact on mobility, this approach may offer a better option for post-surgical physical therapy as current nerve block therapies cause temporary paralysis in the affected area. Similarly for the mechanical allodynia test results, three of the four formulations showed statistically better efficacy for a longer duration of time than bupivacaine. The mechanical allodynia test is shorter in duration, reflecting the subject’s innate swift recovery rate to surgical incisions. Nonetheless, the results mirrored the successful results set forth with the thermal hyperalgesia test.お知らせ • Nov 21Channel Therapeutics Corporation Provides Therapeutic Program UpdateChannel Therapeutics Corporation Provided Therapeutic Program Update. Depot Program for Postoperative Nerve Blocks – the Company showed a sustained release of drug over a 96-hour period in animals and is currently performing efficacy studies in animals, with results expected imminently. Eye Pain Program – the eye drops were well tolerated in an animal study and the Company is performing efficacy studies in animal models of eye pain with toxicology studies starting shortly. The results of the efficacy studies are expected in the coming weeks and the toxicology data is expected in late first quarter of 2025. The Company expects to commence Phase II human proof of concept studies in second quarter of 2025, with a readout by the end of 2025. Chronic Pain – the Company is exploring program-specific financing for this program with expectations that the program will be kicked off in first quarter of 2025.New Risk • Nov 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.5m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-US$1.4m). Earnings have declined by 73% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$3.87m market cap).お知らせ • Oct 29Chromocell Therapeutics Corporation Announces Unveiling of Injectable Depot Program for the Treatment of Surgical PainChromocell Therapeutics Corporation announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company's novel NaV1.7 molecule for treating chronic pain and eye pain. There are approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the Unites States for which this analgesic modality might be applicable, providing a robust potential market for the product. The Company believes there are strong synergies between the programs and is building a suite of related products to address multiple different types of pain and methods of delivery, with a drug that has shown no addictive properties in 4 Phase I trials. With these programs, the Company hopes to reduce usage of opioids and other sub-optimal drugs in various indications and expects to be able to take advantage of certain NOPAIN Act provisions if the drugs are approved by the FDA.Board Change • Sep 30High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 3 experienced directors. No highly experienced directors. Independent Director Ezra Friedberg is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 10Chromocell Therapeutics Corporation, Annual General Meeting, Oct 22, 2024Chromocell Therapeutics Corporation, Annual General Meeting, Oct 22, 2024.お知らせ • Aug 08Chromocell Therapeutics Corporation (NYSEAM:CHRO) announces an Equity Buyback for $0.25 million worth of its shares.Chromocell Therapeutics Corporation (NYSEAM:CHRO) announces a share repurchase program. Under the program, the company will repurchase up to $0.25 million worth of its shares. The plan is valid till December 31, 2024.お知らせ • Aug 06+ 1 more updateChromocell Therapeutics Corporation announced a financing transactionChromocell Therapeutics Corporation announced that it will receive $30,000,000 in funding on August 6, 2024. The company will issue common shares in the transaction. The company intends to continue the transaction for more than one year. The company will issue securities pursuant to exemption provided under Regulation D.お知らせ • Apr 02Chromocell Therapeutics Corporation announced delayed annual 10-K filingOn 04/01/2024, Chromocell Therapeutics Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 21Chromocell Therapeutics Corporation Announces Formal Launch of Eye Pain Treatment ProgramChromocell Therapeutics Corp. announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler. The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications. Common acute eye pain indications include corneal foreign body damage or abrasion, acute angle closure glaucoma and post-surgical sequelae. Chronic eye pain indications include autoimmune diseases, dry eye and neuropathic etiologies. Chromocell’s platform uniquely targets the NaV1.7 channels on the cornea with the ability to treat all eye pain indications.お知らせ • Mar 20Chromocell Therapeutics Corp. Appoints Frank Knuettel, Interim CEO, as Permanent CEOChromocell Therapeutics Corp. announced that its interim CEO Frank Knuettel, has been appointed as the Company’s permanent CEO. Mr. Knuettel was previously appointed Interim CEO in July 2023, while currently serving as the Company’s CFO, a role he will continue to fill for the near future.Board Change • Feb 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 2 experienced directors. No highly experienced directors. Independent Director Ezra Friedberg is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 16Chromocell Therapeutics Corporation has completed an IPO in the amount of $6.6 million.Chromocell Therapeutics Corporation has completed an IPO in the amount of $6.6 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,100,000 Price\Range: $6 Transaction Features: Sponsor Backed Offering業績と収益の成長予測NYSEAM:PTHS - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028176274532512/31/2027121-71-7612/31/202664-41-11-1473/31/202628-52-35-35N/A12/31/202517-43-23-23N/A9/30/20257-24-17-17N/A6/30/2025N/A-9-2-2N/A3/31/2025N/A-7-4-4N/A12/31/2024N/A-8-6-6N/A9/30/2024N/A-10-5-5N/A6/30/2024N/A-10-6-6N/A3/31/2024N/A-9-3-3N/A12/31/2023N/A-7-1-1N/A9/30/2023N/A-5-1-1N/A6/30/2023N/A-4-1-1N/A3/31/2023N/A-3-1-1N/A12/31/2022N/A-2-2-2N/A9/30/2022N/A-1-1-1N/A6/30/2022N/A-1-2-2N/A3/31/2022N/A-1-2-2N/A12/31/2021N/A-1-2-2N/A12/31/20200-1-4-4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PTHSは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。収益対市場: PTHS今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: PTHS今後 3 年以内に収益を上げることが予想されます。収益対市場: PTHSの収益 ( 33.6% ) US市場 ( 13% ) よりも速いペースで成長すると予測されています。高い収益成長: PTHSの収益 ( 33.6% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PTHSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 12:26終値2026/06/16 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pelthos Therapeutics Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関James MolloyAlliance Global PartnersOlivia BrayerCantor Fitzgerald & Co.Brandon FolkesH.C. Wainwright & Co.4 その他のアナリストを表示
Breakeven Date Change • May 15The 7 analysts covering Pelthos Therapeutics previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 78% per year to 2027. The company is expected to make a profit of US$32.9m in 2028. Average annual earnings growth of 71% is required to achieve expected profit on schedule.
Major Estimate Revision • Mar 26Consensus EPS estimates fall by 99%The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$5.96 to -US$11.85 per share. Revenue forecast unchanged at US$61.6m. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$58.33. Share price was steady at US$22.74 over the past week.
Breakeven Date Change • Mar 08Forecast breakeven date pushed back to 2028The 6 analysts covering Pelthos Therapeutics previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of US$26.6m in 2028. Average annual earnings growth of 53% is required to achieve expected profit on schedule.
Major Estimate Revision • Mar 03Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$18.0m to US$16.9m. Losses expected to increase from US$13.14 per share to US$14.51. Biotechs industry in the US expected to see average net income decline 8.5% next year. Consensus price target down from US$60.40 to US$58.00. Share price rose 4.0% to US$24.16 over the past week.
New Risk • May 17New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$35m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (409% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$35m). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$89.7m market cap).
Breakeven Date Change • May 15The 7 analysts covering Pelthos Therapeutics previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 78% per year to 2027. The company is expected to make a profit of US$32.9m in 2028. Average annual earnings growth of 71% is required to achieve expected profit on schedule.
お知らせ • May 01Pelthos Therapeutics Inc. to Report Q1, 2026 Results on May 14, 2026Pelthos Therapeutics Inc. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on May 14, 2026
お知らせ • Apr 12Pelthos Therapeutics Inc. Announces Chief Financial Officer TransitionPelthos Therapeutics Inc. announced John M. Gay has been appointed Chief Financial Officer effective April 10, 2026. Mr. Gay succeeds Francis Knuettel II, who served as Pelthos’ Chief Financial Officer since July 2025. Mr. Gay has served as Senior Vice President, Finance & Accounting at Pelthos since 2025. He has more than 25 years of public company finance and accounting experience. Prior to joining Pelthos, he served as Chief Financial Officer of LNHC Inc. (then, a wholly owned subsidiary of Ligand Pharmaceuticals Inc.) and in senior finance roles at several publicly traded companies, including Furiex Pharmaceuticals, which was ultimately acquired by Forest Laboratories. He previously held roles at Deloitte and Arthur Andersen.
お知らせ • Mar 31Pelthos Therapeutics Inc. Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye PainPelthos Therapeutics Inc. announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating CT2000 as a potential treatment for eye pain. Channel Pharmaceutical Corporation owns the rights to CT2000 and its NaV1.7 inhibitor pipeline and is conducting the clinical work through its Australian subsidiary. The placebo-controlled Phase 1b/2a clinical trial will evaluate the safety and clinical efficacy of CT2000 eye drop formulation in patients with moderate to severe dry eye disease with chronic eye pain. The trial will be an adaptive design with a Phase 1 ascending dose study (with acute ocular pain measures) and a Phase 2a maximum tolerated dose study with a 28-day dosing period. Results are anticipated at the end of 2026. In May 2025, Channel announced that it achieved its predefined endpoints in two pre-clinical animal models of its CT2000 eye drop formulations for the treatment of acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease. CT2000 is a novel ophthalmic formulation of Channel’s CC8464 that targets the sodium ion-channel known as NaV1.7, a key factor in the propagation of pain signals in peripheral nerves. NaV1.7 channels are widely expressed in the corneal nerve plexus, making it an attractive target for treating eye pain. Eye pain may occur with various conditions, including severe dry eye disease, trauma and surgery. Existing therapies for eye pain, including steroids, topical non-steroidal anti-inflammatory agents, lubricants, and local anesthetics, are limited in their effectiveness and/or limited in the duration that they may be prescribed because of safety issues. It is estimated that the global chronic ocular pain market will reach $5.3 billion by 2032.
Major Estimate Revision • Mar 26Consensus EPS estimates fall by 99%The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$5.96 to -US$11.85 per share. Revenue forecast unchanged at US$61.6m. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$58.33. Share price was steady at US$22.74 over the past week.
お知らせ • Mar 09Pelthos Therapeutics Inc. to Report Q4, 2025 Results on Mar 19, 2026Pelthos Therapeutics Inc. announced that they will report Q4, 2025 results on Mar 19, 2026
Breakeven Date Change • Mar 08Forecast breakeven date pushed back to 2028The 6 analysts covering Pelthos Therapeutics previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of US$26.6m in 2028. Average annual earnings growth of 53% is required to achieve expected profit on schedule.
Major Estimate Revision • Mar 03Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$18.0m to US$16.9m. Losses expected to increase from US$13.14 per share to US$14.51. Biotechs industry in the US expected to see average net income decline 8.5% next year. Consensus price target down from US$60.40 to US$58.00. Share price rose 4.0% to US$24.16 over the past week.
お知らせ • Jan 13Pelthos Therapeutics Inc. announced that it expects to receive $50 million in fundingPelthos Therapeutics Inc. announced that it has entered into a Venture Loan and Security Agreement with new lender Horizon Technology Finance Corporation, a fund managed by, Horizon Technology Finance Management, LLC for an aggregate principal amount of up to $50 million on January 12, 2026. The company has borrowed $30 million of Term Loans on the same date. The remaining $20 million of Terms Loans may be borrowed under the Loan Agreement upon the achievement by the Company of certain milestones set forth in the Loan Agreement. The Loan Agreement accrue interest at a rate equal to the prime rate plus 3.75% with the prime rate having a floor of 6.75%. The Term Loans are repayable in monthly interest-only payments from March 1, 2026 until February 1, 2029. After the expiration of the Interest-Only Payment Period, beginning on March 1, 2029, the Term Loans will be repayable in 24 equal monthly payments of principal and accrued interest until maturity. if the Borrowers achieve a trailing twelve-month consolidated net revenue of at least $75.0 million, the Term Loans will be repayable in monthly interest-only payments from March 1, 2026 until February 1, 2030. After the expiration of the Extended Interest-Only Payment Period, the Term Loans will be repayable in 12 equal monthly payments of principal and accrued interest until maturity. The Term Loans will mature on January 31, 2031. The company paid a commitment fee in the amount of $300,000 on the Closing Date. The company will pay an additional commitment fee in the amount of 1.0% of the principal amount of the last six Term Loans concurrently with the funding of those six Term Loans.
Recent Insider Transactions • Nov 28Independent Director recently sold US$280k worth of stockOn the 25th of November, Ezra Friedberg sold around 10k shares on-market at roughly US$28.03 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
お知らせ • Nov 17Pelthos Therapeutics Inc., Annual General Meeting, Dec 17, 2025Pelthos Therapeutics Inc., Annual General Meeting, Dec 17, 2025.
お知らせ • Nov 08Pelthos Therapeutics Inc. announced that it has received $18 million in funding from Ligand Pharmaceuticals IncorporatedPelthos Therapeutics Inc. has entered into entered into a securities purchase agreement with certain investors, including Ligand Pharmaceuticals and issued $18,000,000 senior secured notes which are convertible into shares of the Company’s common stock, par value $0.0001 per share on November 6, 2025. The notes have interest at a rate of 8.5% per annum, payable quarterly in arrears. The Notes will mature on November 6, 2027, unless earlier repurchased, redeemed or converted into shares of common stock in accordance with their terms. The Notes will be convertible at an initial conversion price of $34.442.
お知らせ • Nov 05Pelthos Therapeutics Inc. to Report Q3, 2025 Results on Nov 13, 2025Pelthos Therapeutics Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 13, 2025
お知らせ • Oct 10Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum ContagiosumPelthos Therapeutics Inc. announced the launch of Moms against Molluscum, a movement to unite mothers, parents, and other caregivers navigating molluscum contagiosum. The Moms Against Molluscum movement encourages people managing this highly contagious skin infection to visit Moms AgainstMolluscum.com to share their stories and access information about new treatment options, including ZELSUVMI™? (berdazimer) topical gel, 10.3%. Molluscum is a poxvirus and one of the most common skin infections seen by dermatologists, pediatric dermatologists, and pediatricians. The once-daily prescription medication is effective, well-tolerated, and convenient for at-home or on-the-go application and can be used to treat molluscum infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infection.
New Risk • Aug 28New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 428% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-US$6.5m). Earnings have declined by 52% per year over the past 5 years. Shareholders have been substantially diluted in the past year (428% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$72.2m market cap).
お知らせ • Jul 10Pelthos Therapeutics Launches Zelsuvmi™? (Berdazimer) Topical Gel 10.3%, the First and Only Fda-Approved At-Home Treatment for Molluscum ContagiosumPelthos Therapeutics Inc. announced the launch of ZELSUVMI™? (berdazimer) topical gel, 10.3%, for the treatment of molluscumcontagiosum (molluscum) in adults and pediatric patients one year of age and older. ZELSUVMI received a novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infections, a highly contagious viral skin condition. The once-daily prescription medication is effective, well tolerated, and convenient for at-home or on-the-go application and can be used to treat infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI was studied in the largest randomized clinical trial for the treatment of mollusum. The trial was a multicenter, randomized, double-blind, vehicle controlled, parallel-group, Phase 3 study of the efficacy and safety of ZELSUVMI in 891 patients. These patients have waiting a long time for an at-home treatment option. ZELSUVMI is now commercially available through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies via prescription.
お知らせ • Jul 03+ 3 more updatesPelthos Therapeutics Inc. Announces Management ChangesOn July 1, 2025 (the “Closing Date”), Pelthos Therapeutics Inc., a Nevada corporation (formerly known as “Channel Therapeutics Corporation” (the “Company”)), consummated the previously announced merger transaction contemplated by that certain Agreement and Plan of Merger, dated as of April 16, 2025 (the “Merger Agreement”), by and among the Company, CHRO Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), LNHC Inc., a Delaware corporation (“LNHC”), and solely for the purposes of Article III thereof, a Ligand Pharmaceuticals Incorporated, a Delaware corporation and the parent of LNHC (“Ligand”). Pursuant to the Merger Agreement, (i) Merger Sub merged with and into LNHC, with LNHC as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of the Company (the “Merger”) and (ii) the Company’s name was changed from Channel Therapeutics Corporation to Pelthos Therapeutics Inc. In connection with the Merger and pursuant to the terms of the Merger Agreement, at the Effective Time, Francis Knuettel II, Todd Davis, Ezra Friedberg and Chia-Lin Simmons each resigned from the Company’s board of directors (the “Board”). In addition, the size of the Board was increased from five to seven directors. At the Effective Time, one director selected by the Company, namely Dr. Richard Malamut, one director who is the newly-elected Chief Executive Officer of the Company, namely Scott Plesha, four directors selected by LNHC, namely Peter Greenleaf, Matthew Pauls, Todd Davis and Richard Baxter, and one member selected by Nomis Bay, namely Ezra Friedberg, were each appointed to serve as a director of the Company until the next annual meeting of stockholders to be held after the Closing Date or until a successor is duly elected and qualified, or until each such director’s earlier resignation or removal. Effective as of the Closing Date, the following committees of the Board were constituted as follows: Audit Committee: Ezra Friedberg (Chair) and Matthew Pauls. Compensation Committee: Dr. Richard Malamut and Matthew Pauls (Chair). Nominating and Corporate Governance Committee: Dr. Richard Malamut and Peter Greenleaf (Chair). In connection with the Merger, on the Closing Date, Francis Knuettel’s employment as Chief Executive Officer, and President, Treasurer and Secretary of the Company terminated. Additionally, on the Closing Date, Dr. Eric Lang’s employment as Chief Medical Officer of the Company was terminated. In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, the following individuals were appointed to serve as executive officers of the Company: Scott Plesha, age 61, as President and Director. Sai Rangarao, age 41, as Chief Commercial Officer. Sai Rangarao serves as Senior Vice President, Head of Sales, Marketing & Commercial Operations at Pelthos. Mr. Rangarao joined Pelthos in March 2024. He has more than a decade of experience leading, launching, and marketing large and highly differentiated pharmaceutical products, including Otezla®, the only approved oral systemic therapy with a broad indication. Prior to joining Pelthos, Mr. Rangarao was Vice President of Marketing at Collegium Pharmaceutical, where he led marketing for the full product portfolio and Neurology sales. He joined Collegium from BioDelivery Sciences International (BDSI), which was acquired by Collegium in 2022. Under Mr. Rangarao’s leadership as Vice President of Marketing and Commercial Operations at BDSI, the company expanded its pain and neurology product portfolio and increased market share of the company’s lead product BELBUCA®, ultimately leading to the successful sale to Collegium. Before BDSI, he was Head of Dermatology Marketing at Celgene Corporation. At Celgene, Mr. Rangarao was responsible for the commercial efforts of Otezla in dermatology for three consecutive years leading to significant year-over-year market share growth until the product was sold to Amgen for $13 billion. He began his career at Novartis Pharmaceuticals, where he held roles of increasing responsibility across Global R&D, Sales Force Effectiveness, Multichannel, and In-Line Marketing. Mr. Rangarao also served as a key member of the commercial and marketing organization at Novartis that launched COSENTYX® in the U.S. Mr. Rangarao earned an MS in Bioscience Regulatory Affairs from The Johns Hopkins University, an MBA and MS from the New Jersey Institute of Technology, and a BS in Computer Science from Indiana University of Pennsylvania.
New Risk • May 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$4.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.4m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-US$4.2m). Earnings have declined by 57% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$6.47m market cap).
お知らせ • May 15Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using Its Nav1.7 Inhibitor in Multiple Preclinical in Vivo ModelsChannel Therapeutics Corporation announced that it has achieved its predefined endpoints in two pre-clinical animal models of the Company's eye drop formulations ("CT2000") for the treatment of both acute ocular pain as well as chronic ocular surface pain commonly associated with dry eye disease. In the first trial, rabbits were treated with capsaicin (i.e., Pepper spray) to mimic an acute ocular insult in a common, validated model for acute eye pain studies. Following the capsaicin treatment, the rabbits were treated with CT2000, which was dosed four times over a 24-hour period. Pain was measured by the number of paw wipes over 60 seconds (paw wipes are a recognized surrogate of eye pain in animal models). The results showed that CT2000 significantly reduced the number of paw wipes within 15 minutes of administration of capsaicin and that CT2000 continued to show efficacy over a 60-minute period following administration. This eye pain model was only validated for a short duration, with the results summarized in the following graph: Trial Two: In the second trial, benzalkonium chloride was instilled in mice eyes over a multiday period to create a model of dry eye disease (the study was repeated twice). BAC is a detergent that irritates the eyes and simulates dry eye disease. It is this existing market that the Company intends to target with CT2000, in addition to the post operative pain market with recently announced data on the efficacy of Depot formulation, which will be developed for use in post operative nerve blocks.
お知らせ • Dec 19Channel Therapeutics Announces Positive Efficacy Data for A Depot Formulation of A NaV1.7 Inhibitor in A Preclinical in Vivo Nerve Block ModelChannel Therapeutics Corporation, announced that it achieved its endpoints in two pre-clinical in vivo models of the Company’s nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration. About the trial The Company performed a thermal hyperalgesia test in rodents with a placebo arm, bupivacaine arm and four arms of the main formulations of the Company’s molecule. The Company also performed a mechanical allodynia test in rodents with the same arms as above. For both models, the drugs were administered as a sciatic nerve block. All four Company formulations showed a depot effect in excess of four days, an improvement over bupivacaine, the current standard of care. Results The results of the thermal hyperalgesia results are shown in the chart below. After thirty minutes, three of the four formulations showed materially better efficacy than bupivacaine, with each of the three being statistically superior to placebo for more than two days longer than bupivacaine. One of the formulations remained statistically superior to placebo for more than four days. Further, as NaV1.7 does not have an impact on mobility, this approach may offer a better option for post-surgical physical therapy as current nerve block therapies cause temporary paralysis in the affected area. Similarly for the mechanical allodynia test results, three of the four formulations showed statistically better efficacy for a longer duration of time than bupivacaine. The mechanical allodynia test is shorter in duration, reflecting the subject’s innate swift recovery rate to surgical incisions. Nonetheless, the results mirrored the successful results set forth with the thermal hyperalgesia test.
お知らせ • Nov 21Channel Therapeutics Corporation Provides Therapeutic Program UpdateChannel Therapeutics Corporation Provided Therapeutic Program Update. Depot Program for Postoperative Nerve Blocks – the Company showed a sustained release of drug over a 96-hour period in animals and is currently performing efficacy studies in animals, with results expected imminently. Eye Pain Program – the eye drops were well tolerated in an animal study and the Company is performing efficacy studies in animal models of eye pain with toxicology studies starting shortly. The results of the efficacy studies are expected in the coming weeks and the toxicology data is expected in late first quarter of 2025. The Company expects to commence Phase II human proof of concept studies in second quarter of 2025, with a readout by the end of 2025. Chronic Pain – the Company is exploring program-specific financing for this program with expectations that the program will be kicked off in first quarter of 2025.
New Risk • Nov 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.5m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-US$1.4m). Earnings have declined by 73% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$3.87m market cap).
お知らせ • Oct 29Chromocell Therapeutics Corporation Announces Unveiling of Injectable Depot Program for the Treatment of Surgical PainChromocell Therapeutics Corporation announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company's novel NaV1.7 molecule for treating chronic pain and eye pain. There are approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the Unites States for which this analgesic modality might be applicable, providing a robust potential market for the product. The Company believes there are strong synergies between the programs and is building a suite of related products to address multiple different types of pain and methods of delivery, with a drug that has shown no addictive properties in 4 Phase I trials. With these programs, the Company hopes to reduce usage of opioids and other sub-optimal drugs in various indications and expects to be able to take advantage of certain NOPAIN Act provisions if the drugs are approved by the FDA.
Board Change • Sep 30High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 3 experienced directors. No highly experienced directors. Independent Director Ezra Friedberg is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 10Chromocell Therapeutics Corporation, Annual General Meeting, Oct 22, 2024Chromocell Therapeutics Corporation, Annual General Meeting, Oct 22, 2024.
お知らせ • Aug 08Chromocell Therapeutics Corporation (NYSEAM:CHRO) announces an Equity Buyback for $0.25 million worth of its shares.Chromocell Therapeutics Corporation (NYSEAM:CHRO) announces a share repurchase program. Under the program, the company will repurchase up to $0.25 million worth of its shares. The plan is valid till December 31, 2024.
お知らせ • Aug 06+ 1 more updateChromocell Therapeutics Corporation announced a financing transactionChromocell Therapeutics Corporation announced that it will receive $30,000,000 in funding on August 6, 2024. The company will issue common shares in the transaction. The company intends to continue the transaction for more than one year. The company will issue securities pursuant to exemption provided under Regulation D.
お知らせ • Apr 02Chromocell Therapeutics Corporation announced delayed annual 10-K filingOn 04/01/2024, Chromocell Therapeutics Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 21Chromocell Therapeutics Corporation Announces Formal Launch of Eye Pain Treatment ProgramChromocell Therapeutics Corp. announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler. The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications. Common acute eye pain indications include corneal foreign body damage or abrasion, acute angle closure glaucoma and post-surgical sequelae. Chronic eye pain indications include autoimmune diseases, dry eye and neuropathic etiologies. Chromocell’s platform uniquely targets the NaV1.7 channels on the cornea with the ability to treat all eye pain indications.
お知らせ • Mar 20Chromocell Therapeutics Corp. Appoints Frank Knuettel, Interim CEO, as Permanent CEOChromocell Therapeutics Corp. announced that its interim CEO Frank Knuettel, has been appointed as the Company’s permanent CEO. Mr. Knuettel was previously appointed Interim CEO in July 2023, while currently serving as the Company’s CFO, a role he will continue to fill for the near future.
Board Change • Feb 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 2 experienced directors. No highly experienced directors. Independent Director Ezra Friedberg is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 16Chromocell Therapeutics Corporation has completed an IPO in the amount of $6.6 million.Chromocell Therapeutics Corporation has completed an IPO in the amount of $6.6 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,100,000 Price\Range: $6 Transaction Features: Sponsor Backed Offering